Evidence map›Paper›PMID 32459834›Full record

ReviewThe Journal of clinical endocrinology and metabolism2020

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists.

Jens Juul Holst, Mette Marie Rosenkilde

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 4 pooled it
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 4 syntheses or guidelines pooled it, 187 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Effect of GLP-1 receptor agonist on nutrient intake: A narrative review.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026
    Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. The evolving landscape of obesity pharmacotherapy.Nature reviews. Drug discovery · 2026
    Review
  14. Altered GScience advances · 2026
    Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jens Juul HolstDepartment of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Mette Marie RosenkildeDepartment of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
University of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2 hormones responsible for the amplification of insulin secretion after oral as opposed to intravenous nutrient administration are the gut peptides, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). However, whereas GLP-1 also inhibits appetite and food intake and improves glucose regulation in patients with type 2 diabetes (T2DM), GIP seems to be devoid of these activities, although the 2 hormones as well as their receptors are highly related. In fact, numerous studies have suggested that GIP may promote obesity. However, chimeric peptides, combining elements of both peptides and capable of activating both receptors, have recently been demonstrated to have remarkable weight-losing and glucose-lowering efficacy in obese individuals with T2DM. At the same time, antagonists of the GIP receptor have been reported to reduce weight gain/cause weight loss in experimental animals including nonhuman primates. This suggests that both agonists and antagonist of the GIP receptor should be useful, at least for weight-losing therapy. How is this possible? We here review recent experimental evidence that agonist-induced internalization of the two receptors differs markedly and that modifications of the ligand structures, as in co-agonists, profoundly influence these cellular processes and may explain that an antagonist may activate while an agonist may block receptor signaling.

Indexed as

Anti-Obesity AgentsAppetiteBlood GlucoseDiabetes Mellitus, Type 2Gastric Inhibitory PolypeptideGlucagon-Like Peptide 1HumansHypoglycemic AgentsIncretinsObesityReceptors, Gastrointestinal HormoneSignal TransductionWeight LossAnti-Obesity AgentsBlood GlucoseGastric Inhibitory Polypeptidegastric inhibitory polypeptide receptorGlucagon-Like Peptide 1Hypoglycemic AgentsIncretinsReceptors, Gastrointestinal Hormoneco-agonistsGLP-1glucose-dependent insulinotropic polypeptidereceptor internalizationtype 2 diabetesweight-losing therapy

Identifiers

PMID32459834
PMCPMC7308078
OpenAlexW3030023482

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.